Efficacy and Safety to Evaluate Relugolix with Heavy Menstrual Bleeding Associated with Uterine Fibroids

Update Il y a 4 ans
Reference: EUCTR2016-005113-50

Woman Man

  • | Country :
  • -
  • | organs :
  • -
  • | Specialty :
  • -

Extract

•To determine the benefit of relugolix 40 mg once daily co-administered with low dose estradiol and norethindrone acetate compared with placebo for 24 weeks on heavy menstrual bleeding associated with uterine fibroids.


Inclusion criteria

  • heavy menstrual bleeding associated with uterine fibroids

Links